Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis. (December 2019)

• Record Type: Journal Article
• Authors: Ting, Choo-Yuen; Liew, Su-May; Price, Amy; Gan, Gin-Gin; Bee-Lan Ong, Diana; Tan, Soo-Yong; Bee, Ping-Chong
• Is Part Of: Critical reviews in oncology/hematology. Volume 144(2019)
• Publication Date: 2019-12
• Subjects: MiR microRNA -- DLBCL diffuse large B-cell lymphoma -- PFS progression free survival -- DR/PFS disease relapse/progression free survival period -- HR hazard ratio -- CI confidence interval -- FFPE formalin-fixed-paraffin-embedded -- RCHOP rituximab cyclophosphamide, doxorubicin, vincristine and prednisone -- PI3K/Akt phosphoinositide-3-kinase–protein kinase B/Akt signaling pathway; MicroRNA -- Diffuse large B-cell lymphoma -- Disease relapse -- Progression free survival period -- Treatment response -- Predict; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2019.102818
• Languages: English
• ISSNs: 1040-8428

Abstract

Highlights: Background and why the study was undertaken? What are the new findings from this meta-analysis? How is the potential significance of the results how might it impact on clinical practice? Abstract: The clinical significance of aberrantly expressed microRNAs in predicting treatment response to chemotherapy in diffuse large B-cell lymphoma patients (DLBCL) remains uncertain. Feasibility of microRNA testing to predict treatment outcome was evaluated. Twenty-two types of aberrantly expressed microRNAs were associated with poor treatment response; pooled hazard ratio (HR) was 2.14 [95%CI:1.78-2.57, P < 0.00001]. DLBCL patients with aberrant expression of miR-155, miR-17/92 clusters, miR-21, miR-224, or miR-146b-5p had a higher risk of treatment resistance or shorter period of disease relapse/progression free survival, with HR = 2.71 (95%CI:1.66-4.42, P < 0.0001), HR = 2.70 (95%CI:1.50-4.85, P = 0.0010), HR = 2.20 (95%CI:1.31-3.69, P = 0.003), HR = 2.07 (95%CI:1.50-2.86, P < 0.00001), HR = 2.26 (95%CI:1.40-3.65, P = 0.0009), respectively. The association between aberrant expression of microRNAs and treatment response appears to be stronger in formalin-fixed-paraffin-embedded tissue (HR = 2.41, 95%CI:1.79-3.25, P < 0.00001) than in fresh-frozen samples (HR = 1.94, 95%CI: 1.22–3.08, P = 0.005) and peripheral blood samples (HR = 1.94, 95%CI:1.53-2.46, P < 0.00001). Mir-155, miR-17/92 clusters, miR-21, miR-224, and mir-146b-5p have value in predicting treatment response to chemotherapy in DLBCL.